{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:18:19Z","timestamp":1787818699392,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polygenic risk scores (PRS) are increasingly being incorporated into clinical care, yet optimal strategies for communicating PRS results to patients and clinicians remain undefined. Effective report design is critical to ensure comprehension and appropriate use, particularly for complex conditions such as prostate cancer where screening decisions are nuanced. We developed and pilot tested patient-facing materials to communicate integrated polygenic and monogenic risk for prostate cancer in the context of a randomized clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We designed a summary report and accompanying Frequently Asked Questions (FAQ) page to communicate prostate cancer genetic risk within the Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS). Materials were developed through an iterative, multidisciplinary process informed by existing literature on genomic risk communication. We conducted semi-structured interviews with a national sample of eight men eligible for prostate cancer screening to evaluate comprehension, interpretation of visual elements, perceived usefulness, and preferences for improvement. Interviews were transcribed and analyzed using reflexive thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants generally found the summary report and FAQ page understandable and visually engaging. Graphical displays of absolute risk, particularly pictograph arrays, facilitated comprehension and helped contextualize risk. Visual cues such as color and bold formatting effectively directed attention to key information, with red coloring perceived as particularly salient for high-risk results. In contrast, more complex visualizations, including bell curves and incidence curves, were frequently misunderstood or not interpreted as intended. Participants expressed a desire for clearer guidance regarding next steps and additional accessible information, suggesting supplementary resources such as hyperlinks or QR codes. Concerns about readability included small font size and high text density.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this qualitative pilot study, patient-facing materials for communicating prostate cancer PRS were generally well received, with specific design features such as simple visualizations and clear formatting enhancing understanding. Findings highlight the importance of intuitive risk displays and actionable guidance in PRS reporting. These results provide practical insights to inform the design of genomic risk reports as PRS-based prostate cancer screening approaches move toward clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05926102; date of registry: July 3, 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-026-02416-4","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:06:00Z","timestamp":1785405960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and pilot testing of a prostate cancer polygenic risk report"],"prefix":"10.1186","volume":"19","author":[{"given":"Julia N.","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Danowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley L.","family":"Gerety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla L.","family":"Clayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Antwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes G.","family":"Bertero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Brunette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Guentert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall J.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Vassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2416_CR1","doi-asserted-by":"publisher","unstructured":"Roberts E, Flaum N, Evans DG. Clinical implementation of polygenic risk scores. Eur J Hum Genet. Published online September 29, 2025:1\u20133. https:\/\/doi.org\/10.1038\/s41431-025-01931-9.","DOI":"10.1038\/s41431-025-01931-9"},{"issue":"4","key":"2416_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.70084","volume":"34","author":"R Purvis","year":"2025","unstructured":"Purvis R, Taylor N, Young MA, James P, Forrest LE. Readiness and leadership for the implementation of polygenic risk scores: genetic healthcare providers\u2019 perspectives in the hereditary cancer context. J Genet Couns. 2025;34(4):e70084. https:\/\/doi.org\/10.1002\/jgc4.70084.","journal-title":"J Genet Couns"},{"issue":"1","key":"2416_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xhgg.2025.100554","volume":"7","author":"SA Suckiel","year":"2025","unstructured":"Suckiel SA, Golfinopoulos L, Scherr CL, et al. Healthcare professionals\u2019 experiences returning monogenic, polygenic, and integrated risk results in the eMERGE study. Hum Genet Genomics Adv. 2025;7(1):100554. https:\/\/doi.org\/10.1016\/j.xhgg.2025.100554.","journal-title":"Hum Genet Genomics Adv"},{"issue":"3","key":"2416_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jgc4.1668","volume":"32","author":"H Wand","year":"2023","unstructured":"Wand H, Kalia SS, Helm BM, et al. Clinical genetic counseling and translation considerations for polygenic scores in personalized risk assessments: a practice resource from the National Society of Genetic Counselors. J Genet Couns. 2023;32(3):558\u201375. https:\/\/doi.org\/10.1002\/jgc4.1668.","journal-title":"J Genet Couns"},{"key":"2416_CR5","doi-asserted-by":"publisher","unstructured":"Kullo IJ. Clinical use of polygenic risk scores: current status, barriers and future directions. Nat Rev Genet. Published online October 10, 2025. https:\/\/doi.org\/10.1038\/s41576-025-00900-8.","DOI":"10.1038\/s41576-025-00900-8"},{"issue":"6","key":"2416_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101414","volume":"27","author":"R Purvis","year":"2025","unstructured":"Purvis R, Forrest LE, Young MA, Limb S, James P, Taylor N. Defining next steps in the clinical implementation of polygenic scores: A landscape analysis of professional groups\u2019 perspectives. Genet Med Off J Am Coll Med Genet. 2025;27(6):101414. https:\/\/doi.org\/10.1016\/j.gim.2025.101414.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"9","key":"2416_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219\u201324. https:\/\/doi.org\/10.1038\/s41588-018-0183-z.","journal-title":"Nat Genet"},{"issue":"5","key":"2416_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41591-022-01767-6","volume":"28","author":"L Hao","year":"2022","unstructured":"Hao L, Kraft P, Berriz GF, et al. Development of a clinical polygenic risk score assay and reporting workflow. Nat Med. 2022;28(5):1006\u201313. https:\/\/doi.org\/10.1038\/s41591-022-01767-6.","journal-title":"Nat Med"},{"key":"2416_CR9","doi-asserted-by":"publisher","unstructured":"Vassy JL, Dornisch AM, Karunamuni R, et al. Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study. Nat Cancer. Published online January 26, 2026:1-16. https:\/\/doi.org\/10.1038\/s43018-025-01103-0","DOI":"10.1038\/s43018-025-01103-0"},{"key":"2416_CR10","doi-asserted-by":"publisher","unstructured":"Lennon NJ, Kottyan LC, Kachulis C, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat Med. Published online February 19, 2024:1-8. https:\/\/doi.org\/10.1038\/s41591-024-02796-z.","DOI":"10.1038\/s41591-024-02796-z"},{"issue":"13","key":"2416_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1200\/JCO.23.00295","volume":"42","author":"N Mars","year":"2024","unstructured":"Mars N, Kerminen S, Tamlander M, et al. Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(13):1477\u201387. https:\/\/doi.org\/10.1200\/JCO.23.00295.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2416_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100006","volume":"25","author":"JE Linder","year":"2023","unstructured":"Linder JE, Allworth A, Bland ST, et al. Returning integrated genomic risk and clinical recommendations: The eMERGE study. Genet Med. 2023;25(4):100006. https:\/\/doi.org\/10.1016\/j.gim.2023.100006.","journal-title":"Genet Med"},{"issue":"11","key":"2416_CR13","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.ajhg.2023.10.001","volume":"110","author":"JL Vassy","year":"2023","unstructured":"Vassy JL, Brunette CA, Lebo MS, et al. The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care. Am J Hum Genet. 2023;110(11):1841\u201352. https:\/\/doi.org\/10.1016\/j.ajhg.2023.10.001.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"2416_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jama.2025.24784","volume":"335","author":"LJ Esserman","year":"2026","unstructured":"Esserman LJ, Fiscalini AS, Naeim A, et al. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA. 2026;335(9):763\u201374. https:\/\/doi.org\/10.1001\/jama.2025.24784.","journal-title":"JAMA"},{"issue":"14","key":"2416_CR15","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh JK, Bancroft EK, Saunders E, et al. Assessment of a polygenic risk score in screening for prostate cancer. N Engl J Med. 2025;392(14):1406\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2407934.","journal-title":"N Engl J Med"},{"issue":"16","key":"2416_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333(16):1433\u201346. https:\/\/doi.org\/10.1001\/jama.2025.0228.","journal-title":"JAMA"},{"issue":"6","key":"2416_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046\u201355. https:\/\/doi.org\/10.1016\/j.eururo.2013.12.062.","journal-title":"Eur Urol"},{"key":"2416_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. https:\/\/doi.org\/10.1136\/bmj.k3519.","journal-title":"BMJ"},{"issue":"1","key":"2416_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76(1):43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009.","journal-title":"Eur Urol"},{"issue":"3","key":"2416_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.euo.2023.11.020","volume":"7","author":"BV Stone","year":"2024","unstructured":"Stone BV, Labban M, Beatrici E, et al. The association of county-level prostate-specific antigen screening with metastatic prostate cancer and prostate cancer mortality. Eur Urol Oncol. 2024;7(3):563\u20139. https:\/\/doi.org\/10.1016\/j.euo.2023.11.020.","journal-title":"Eur Urol Oncol"},{"issue":"18","key":"2416_CR21","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer. JAMA. 2018;319(18):1901\u201313. https:\/\/doi.org\/10.1001\/jama.2018.3710.","journal-title":"JAMA"},{"issue":"1","key":"2416_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/ju.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46\u201353. https:\/\/doi.org\/10.1097\/ju.0000000000003491.","journal-title":"J Urol"},{"key":"2416_CR23","unstructured":"Moses KA, Sprenkle PC, Bahler C, et al. NCCN Guidelines Version 1.2025: Prostate Cancer Early Detection. Published online 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf"},{"key":"2416_CR24","unstructured":"American Cancer Society. American Cancer Society Recommendations for Prostate Cancer Early Detection. 2019."},{"issue":"5","key":"2416_CR25","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300289","volume":"3","author":"IP Garraway","year":"2024","unstructured":"Garraway IP, Carlsson SV, Nyame YA, et al. Prostate cancer foundation screening guidelines for Black men in the United States. NEJM Evid. 2024;3(5):EVIDoa2300289. https:\/\/doi.org\/10.1056\/EVIDoa2300289.","journal-title":"NEJM Evid"},{"issue":"4","key":"2416_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/09691413221119238","volume":"29","author":"SD Jackson","year":"2022","unstructured":"Jackson SD, de la Rue MR, Greenslade TP, et al. Screening asymptomatic men for prostate cancer: a comparison of international guidelines on prostate-specific antigen testing. J Med Screen. 2022;29(4):268\u201371. https:\/\/doi.org\/10.1177\/09691413221119238.","journal-title":"J Med Screen"},{"issue":"6","key":"2416_CR27","doi-asserted-by":"publisher","first-page":"e2414582","DOI":"10.1001\/jamanetworkopen.2024.14582","volume":"7","author":"HS Iyer","year":"2024","unstructured":"Iyer HS, Stone BV, Roscoe C, et al. Access to prostate-specific antigen testing and mortality among men with prostate cancer. JAMA Netw Open. 2024;7(6):e2414582. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.14582.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2416_CR28","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","volume":"55","author":"A Wang","year":"2023","unstructured":"Wang A, Shen J, Rodriguez AA, et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023;55(12):2065\u201374. https:\/\/doi.org\/10.1038\/s41588-023-01534-4.","journal-title":"Nat Genet"},{"issue":"10","key":"2416_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/jmg-2024-109845","volume":"61","author":"R Hall","year":"2024","unstructured":"Hall R, Bancroft E, Pashayan N, Kote-Jarai Z, Eeles RA. Genetics of prostate cancer: a review of latest evidence. J Med Genet. 2024;61(10):915\u201326. https:\/\/doi.org\/10.1136\/jmg-2024-109845.","journal-title":"J Med Genet"},{"key":"2416_CR30","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)): Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 3.2026. National Comprehensive Cancer Network; 2026. https:\/\/www.nccn.org"},{"key":"2416_CR31","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Genetic\/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. Version 1.2025. National Comprehensive Cancer Network; 2025. https:\/\/www.nccn.org"},{"key":"2416_CR32","unstructured":"PDQ Cancer Genetics Editorial Board. PDQ Cancer Genetics Risk Assessment and Counseling. January 3, 2025. Accessed March 19, 2026. https:\/\/www.cancer.gov\/publications\/pdq\/information-summaries\/genetics\/risk-assessment-hp-pdq"},{"key":"2416_CR33","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer Early Detection. Version 2.2026. National Comprehensive Cancer Network; 2026. https:\/\/www.nccn.org"},{"issue":"5","key":"2416_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100804","volume":"25","author":"HV Reddi","year":"2023","unstructured":"Reddi HV, Wand H, Funke B, et al. Laboratory perspectives in the development of polygenic risk scores for disease: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(5):100804. https:\/\/doi.org\/10.1016\/j.gim.2023.100804.","journal-title":"Genet Med"},{"key":"2416_CR35","doi-asserted-by":"publisher","unstructured":"Mackley MP, Richer J, Guerin A, et al. Mainstreaming of clinical genetic testing: a conceptual framework. Genet Med Off J Am Coll Med Genet. Published online May 22, 2025:101465. https:\/\/doi.org\/10.1016\/j.gim.2025.101465.","DOI":"10.1016\/j.gim.2025.101465"},{"issue":"8","key":"2416_CR36","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/s41436-021-01162-5","volume":"23","author":"BD Jenkins","year":"2021","unstructured":"Jenkins BD, Fischer CG, Polito CA, et al. The 2019 US medical genetics workforce: a focus on clinical genetics. Genet Med. 2021;23(8):1458\u201364. https:\/\/doi.org\/10.1038\/s41436-021-01162-5.","journal-title":"Genet Med"},{"issue":"5","key":"2416_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):5. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"7","key":"2416_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1089\/gtmb.2011.0328","volume":"16","author":"MT Scheuner","year":"2012","unstructured":"Scheuner MT, Hilborne L, Brown J, Lubin IM. A report template for molecular genetic tests designed to improve communication between the clinician and laboratory. Genet Test Mol Biomark. 2012;16(7):761\u20139. https:\/\/doi.org\/10.1089\/gtmb.2011.0328.","journal-title":"Genet Test Mol Biomark"},{"key":"2416_CR39","unstructured":"Cheam L, Gillespie C, Cabrera R, Antwi AA, Vassy JL, Clayman ML. Veterans\u2019 perspective on polygenic risk scores in prostate cancer screening. Abstract presented at International Conference on Communication in Healthcare, Ottawa, Ontario. 2025."},{"key":"2416_CR40","volume-title":"Primary care clinicians\u2019 views on polygenic risk scores and shared decision-making in prostate cancer screening: Insights for developing implementation strategies","author":"JL Vassy","year":"2025","unstructured":"Vassy JL, Gillespie C, Cheam L, Antwi AA, Cabrera R, Clayman ML. Primary care clinicians\u2019 views on polygenic risk scores and shared decision-making in prostate cancer screening: Insights for developing implementation strategies. Hollywood, FL: Abstract presented at the Society for General Internal Medicine Annual Meeting; 2025."},{"issue":"1","key":"2416_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/26895269.2022.2129597","volume":"24","author":"V Braun","year":"2023","unstructured":"Braun V, Clarke V. Toward good practice in thematic analysis: avoiding common problems and be(com)ing a knowing researcher. Int J Transgender Health. 2023;24(1):1\u20136. https:\/\/doi.org\/10.1080\/26895269.2022.2129597.","journal-title":"Int J Transgender Health"},{"issue":"16","key":"2416_CR42","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jama.2025.13655","volume":"334","author":"BJ Zikmund-Fisher","year":"2025","unstructured":"Zikmund-Fisher BJ, Thorpe A, Fagerlin A. How to Communicate Medical Numbers. JAMA. 2025;334(16):1474\u20135. https:\/\/doi.org\/10.1001\/jama.2025.13655.","journal-title":"JAMA"},{"issue":"1","key":"2416_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12920-021-01056-0","volume":"14","author":"DG Brockman","year":"2021","unstructured":"Brockman DG, Petronio L, Dron JS, et al. Design and user experience testing of a polygenic score report: a qualitative study of prospective users. BMC Med Genomics. 2021;14(1):238. https:\/\/doi.org\/10.1186\/s12920-021-01056-0.","journal-title":"BMC Med Genomics"},{"issue":"9","key":"2416_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41431-022-01091-0","volume":"30","author":"ZC Deans","year":"2022","unstructured":"Deans ZC, Ahn JW, Carreira IM, et al. Recommendations for reporting results of diagnostic genomic testing. Eur J Hum Genet. 2022;30(9):1011\u20136. https:\/\/doi.org\/10.1038\/s41431-022-01091-0.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"2416_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41431-022-01091-0","volume":"30","author":"ZC Deans","year":"2022","unstructured":"Deans ZC, Ahn JW, Carreira IM, et al. Recommendations for reporting results of diagnostic genomic testing. Eur J Hum Genet. 2022;30(9):1011\u20136. https:\/\/doi.org\/10.1038\/s41431-022-01091-0.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2416_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01117-8","volume":"14","author":"ACF Lewis","year":"2022","unstructured":"Lewis ACF, Perez EF, Prince AER, et al. Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization. Genome Med. 2022;14(1):114. https:\/\/doi.org\/10.1186\/s13073-022-01117-8.","journal-title":"Genome Med"},{"key":"2416_CR47","doi-asserted-by":"publisher","unstructured":"Goldberg SR, Ko LK, Hsu L, et al. Patient Perspectives on Personalized Risk Communication Using Polygenic Risk Scores to Inform Colorectal Cancer Screening Decisions. AJPM Focus. 2025;4(1). https:\/\/doi.org\/10.1016\/j.focus.2024.100308.","DOI":"10.1016\/j.focus.2024.100308"},{"issue":"1","key":"2416_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12920-024-02079-z","volume":"18","author":"GL Hollitt","year":"2025","unstructured":"Hollitt GL, Hassall MM, Siggs OM, Craig JE, Souzeau E. Development and evaluation of patient-centred polygenic risk score reports for glaucoma screening. BMC Med Genomics. 2025;18(1):21. https:\/\/doi.org\/10.1186\/s12920-024-02079-z.","journal-title":"BMC Med Genomics"},{"key":"2416_CR49","doi-asserted-by":"publisher","unstructured":"Ratner D, Vassy JL. Clinical translation of polygenic scores for prostate cancer screening. Nat Rev Urol. Published online October 13, 2025. https:\/\/doi.org\/10.1038\/s41585-025-01095-7.","DOI":"10.1038\/s41585-025-01095-7"},{"key":"2416_CR50","doi-asserted-by":"publisher","DOI":"10.4135\/9781036234386","volume-title":"Qualitative methods for health research","author":"J Green","year":"2018","unstructured":"Green J, Thorogood N. Qualitative methods for health research. 4th ed. SAGE Publications Ltd; 2018.","edition":"4th ed"},{"issue":"1","key":"2416_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. <article-title update=\"added\">How many interviews are enough? Field Methods. 2006;18(1):59\u201382. https:\/\/doi.org\/10.1177\/1525822X05279903.","journal-title":"Field Methods"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-026-02416-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02416-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02416-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:36:43Z","timestamp":1787816203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-026-02416-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2416"],"URL":"https:\/\/doi.org\/10.1186\/s12920-026-02416-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9328730\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) and this qualitative interview substudy were approved by the Department of Veterans Affairs Central Institutional Review Board (Protocol #23\u201339; amendment #E23-57). All participants provided informed consent to participate in the study. This study adhered to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.J.L. is a scientific advisory board member for FYR Diagnostics, Everygene, and AGRF Ltd. All other authors declare that they have no competing interests relevant to the presented work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"137"}}